Compare MMLP & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MMLP | RFL |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Real Estate |
| Sector | Energy | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.1M | 92.6M |
| IPO Year | 2002 | 2017 |
| Metric | MMLP | RFL |
|---|---|---|
| Price | $2.45 | $2.13 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 19.7K | ★ 245.4K |
| Earning Date | 04-22-2026 | 06-10-2026 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,653,009,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.65 | ★ 43.96 |
| 52 Week Low | $1.89 | $1.12 |
| 52 Week High | $3.54 | $3.96 |
| Indicator | MMLP | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 53.23 | 43.37 |
| Support Level | $2.22 | $1.21 |
| Resistance Level | $2.49 | $3.96 |
| Average True Range (ATR) | 0.12 | 0.26 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 82.05 | 16.00 |
Martin Midstream Partners LP has a diverse set of operations focused on the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products, including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing, and distribution; and natural gas liquids marketing, distribution and transportation services. The company operates in four segment Terminalling and storage, Transportation, Sulfur service, and Specialty products segment. The majority of the revenue is derived from the Specialty products segment.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.